Roche Pharmaceuticals is currently working on their Huntingtin Lowering drug, RG6042 (formerly known as IONIS-HTTRx). In the letter Patient Partnership Director, Mai-Lise Nguyen, write about the company and their philosophy on working with the HD patient community.
On behalf of the Roche HD team Nguyen writes: – Since taking over development of RG6042 from Ionis at the end of 2017, we have and will continue to engage with the community.
The safety of the drug, and some of the short term effects, have been measured in 46 participants. Now it’s important to evaluate the longer-term safety. The pharmaceutical company is therefore currently planning a longer, larger global study.
– With the support of the HD community we are working with urgency and care to develop an appropriate clinical development programme that answers important questions around RG6042, Nguyen states.
– We look forward to providing you with additional updates in September.
Find the full letter here: Letter from Roche